Total Payments
$8,192
2024 Payments
$2,157
Companies
31
Transactions
219
Medicare Patients
3,767
Medicare Billing
$372,991
Payment Breakdown by Category
Food & Beverage$8,158 (99.6%)
Education$34.33 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,158 | 217 | 99.6% |
| Education | $34.33 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $1,703 | 44 | $0 (2024) |
| BIOTRONIK INC. | $1,429 | 24 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,283 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $486.58 | 13 | $0 (2024) |
| Abbott Laboratories | $375.35 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $334.80 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $318.59 | 13 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $238.58 | 12 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $233.57 | 5 | $0 (2023) |
| Kiniksa Pharmaceuticals International, plc | $179.18 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,157 | 73 | Abbott Laboratories ($375.35) |
| 2023 | $1,569 | 60 | Impulse Dynamics (USA) Inc. ($233.57) |
| 2022 | $2,311 | 44 | BIOTRONIK INC. ($767.26) |
| 2021 | $1,445 | 25 | BOSTON SCIENTIFIC CORPORATION ($631.34) |
| 2020 | $413.58 | 9 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($182.13) |
| 2019 | $297.00 | 8 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($210.56) |
All Payment Transactions
219 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $93.34 | General |
| Category: Heart Failure | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/26/2024 | BIOTRONIK INC. | BIOMONITOR (Device) | Food and Beverage | In-kind items and services | $63.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/06/2024 | BIOTRONIK INC. | Selectra (Device) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Cardiovascular | ||||||
| 11/01/2024 | Abbott Laboratories | ENSITE (Device) | Food and Beverage | In-kind items and services | $177.04 | General |
| Category: Electrophysiology | ||||||
| 10/30/2024 | BIOTRONIK INC. | Selectra (Device) | Food and Beverage | In-kind items and services | $58.66 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $26.84 | General |
| Category: Cardiovascular | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $1.01 | General |
| Category: Cardiovascular | ||||||
| 10/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Diabetes | ||||||
| 10/04/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Not Applicable | ||||||
| 10/01/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Not Applicable | ||||||
| 09/27/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: Genetic Disease | ||||||
| 09/24/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $22.71 | General |
| Category: Coronary | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/16/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $86.70 | General |
| Category: General - Therapies_CRM | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $25.86 | General |
| Category: Cardiovascular | ||||||
| 09/13/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: Not Applicable | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/05/2024 | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA (Device) | Food and Beverage | In-kind items and services | $44.99 | General |
| Category: Transcatheter Heart Valves | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 3,133 | 4,112 | $1.2M | $308,011 |
| 2022 | 18 | 634 | 722 | $225,910 | $64,980 |
Total Patients
3,767
Total Services
4,834
Medicare Billing
$372,991
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 503 | 857 | $261,385 | $91,845 | 35.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 224 | 234 | $215,046 | $42,724 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 194 | 268 | $108,808 | $40,627 | 37.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 209 | $46,398 | $14,572 | 31.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 228 | 241 | $55,671 | $14,495 | 26.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 84 | 88 | $51,480 | $13,420 | 26.1% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 46 | 46 | $41,262 | $10,810 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $36,880 | $10,622 | 28.8% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 67 | 147 | $20,286 | $8,911 | 43.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 458 | 547 | $57,982 | $6,790 | 11.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 33 | $23,298 | $6,110 | 26.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 58 | $20,126 | $5,763 | 28.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 52 | 77 | $15,632 | $5,483 | 35.1% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 12 | 12 | $31,776 | $5,359 | 16.9% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 41 | 51 | $14,892 | $4,799 | 32.2% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 105 | 109 | $17,767 | $2,419 | 13.6% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 57 | 117 | $9,711 | $2,318 | 23.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 41 | 42 | $18,480 | $2,014 | 10.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 34 | $7,140 | $1,983 | 27.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 18 | $7,416 | $1,955 | 26.4% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 16 | 19 | $6,669 | $1,942 | 29.1% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 17 | 17 | $16,116 | $1,645 | 10.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 48 | 61 | $8,540 | $1,365 | 16.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 177 | 205 | $5,330 | $1,304 | 24.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 42 | 48 | $6,624 | $1,139 | 17.2% |
About Dr. Christopher Chen, MD
Dr. Christopher Chen, MD is a Cardiovascular Disease healthcare provider based in Concord, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2016. The National Provider Identifier (NPI) number assigned to this provider is 1356704407.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Chen, MD has received a total of $8,192 in payments from pharmaceutical and medical device companies, with $2,157 received in 2024. These payments were reported across 219 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($8,158).
As a Medicare-enrolled provider, Chen has provided services to 3,767 Medicare beneficiaries, totaling 4,834 services with total Medicare billing of $372,991. Data is available for 2 years (2022–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Concord, CA
- Active Since 04/05/2016
- Last Updated 08/03/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356704407
Products in Payments
- LifeVest (Device) $1,283
- Edora 8 DR-T (Device) $572.84
- SYNERGY (Device) $537.50
- ELIQUIS (Drug) $439.38
- LEQVIO (Drug) $294.45
- ENSITE (Device) $282.01
- FARXIGA (Drug) $261.30
- XARELTO (Drug) $238.58
- AVVIGO Guidance System (Device) $228.25
- Edora (Device) $211.91
- Solia (Device) $210.92
- LUX-Dx Insertable Cardiac Monitor (Device) $184.40
- Arcalyst (Drug) $179.18
- MANTA (Device) $170.13
- NEXLETOL (Drug) $163.90
- Repatha (Biological) $158.95
- AMVIA EDGE (Device) $133.54
- KENGREAL (Drug) $126.57
- BIOMONITOR (Device) $125.95
- Optimizer (Device) $122.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Concord
Mr. Carleton Nibley, M.d, M.D
Cardiovascular Disease — Payments: $28,039
Cardiovascular Disease $28,039
Shravan Rao, M.d, M.D
Cardiovascular Disease — Payments: $26,019
Cardiovascular Disease $26,019
Howard Min, M.d, M.D
Cardiovascular Disease — Payments: $14,112
Cardiovascular Disease $14,112
Adam Chodosh, M.d, M.D
Cardiovascular Disease — Payments: $7,200
Cardiovascular Disease $7,200
Ayman Hosny, M.d, M.D
Cardiovascular Disease — Payments: $6,535
Cardiovascular Disease $6,535
Dr. Michael Ferguson, Md, MD
Cardiovascular Disease — Payments: $6,470
Cardiovascular Disease $6,470